The FDA’s draft guidance outlines a risk-based framework for assessing the credibility of AI applications in drug, biological product, and medical device regulatory decision-making, emphasizing transparency, data management, and cybersecurity while inviting public comments until April 7, 2025.
View full story…
FDA Releases Draft Guidance on AI in Drug and Medical Device Regulation
